NCIMB

NCIMB

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NCIMB is a long-established, service-oriented microbiology company headquartered in Aberdeen, UK. Its core assets are the UK's largest public repository of bacterial reference strains and a comprehensive suite of analytical and storage services. The company serves a diverse client base in pharmaceuticals, agriculture, food & drink, energy, and environmental services, positioning itself as a critical support partner in the microbiome and synthetic biology ecosystems.

MicrobiomeSynthetic Biology

Technology Platform

Integrated microbiology services platform centered on a proprietary microbial culture collection, complemented by analytical services (ID, sequencing, qPCR, metagenomics), preservation/storage, and proprietary ecotoxicity tests (MARA, LumiMARA).

Opportunities

Growth in microbiome and synthetic biology R&D drives demand for characterized microbial strains and advanced analytical services.
Increasing regulatory needs in food, pharma, and agriculture for microbial ID and QC provide a stable market.
The shift to a bio-based economy creates opportunities in industrial biotechnology support services.

Risk Factors

Revenue is tied to client R&D budgets, which are sensitive to economic and sectoral downturns.
Core services face competition from increasingly accessible in-house technologies.
Operating a certified international collection and serving regulated markets entails significant and evolving compliance burdens.

Competitive Landscape

NCIMB competes with other global culture collections (e.g., ATCC, DSMZ), commercial microbiology testing laboratories, and CROs offering microbial services. Its differentiation lies in the combination of its unique, industry-focused strain collection, its breadth of services from storage to advanced sequencing, and its niche proprietary ecotoxicity tests. It faces pressure from automation and the trend toward bringing simple ID and sequencing capabilities in-house.